Agios Pharmaceuticals (AGIO) reported a loss of $1.69 per share in second-quarter 2024, wider than the Zacks Consensus Estimate of a loss of $1.58. In the year-ago quarter, the company reported a loss of $1.51.AGIO reported revenues of $8.6 million, which missed the Zacks Consensus Estimate of $9.4 million. In the year-ago quarter, the company recorded revenues of $6.7 million.Quarter in DetailIn the reported quarter, revenues were generated entirely from product revenues of Agios’ only marketed drug, Pyruk ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Christopher Raymond - Piper Sandler Gregory Renza - RBC Capital Markets Divya Rao - TD Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organi ...

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.96%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.64 per share when it actually produced a loss of $1.45, delivering a surprise of 11.59%.Over the last four quarters, ...

Exhibit 99.1 Agios Reports Business Highlights and Second Quarter 2024 Financial Results – Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905 Million Purchase Agreement for Vorasidenib Royalty with Royalty Pharma; Agios to Receive a Total of $1.1 Billion in Payments Upon FDA Approval of Vorasidenib – – Reported Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat ...

– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905 Million Purchase Agreement for Vorasidenib Royalty with Royalty Pharma; Agios to Receive a Total of $1.1 Billion in Payments Upon FDA Approval of Vorasidenib – – Reported Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Who are Regularly Transfused – – PYRUKYN ...

Core Insights - Agios Pharmaceuticals reported positive topline data from the Phase 3 ENERGIZE-T study, indicating mitapivat's efficacy across all thalassemia subtypes, with plans to file a supplemental New Drug Application (sNDA) by the end of 2024 [1][2] - The company announced a $905 million purchase agreement with Royalty Pharma for vorasidenib royalty rights, expecting to receive a total of $1.1 billion upon FDA approval of vorasidenib [1][2] - Agios reported net revenue of $8.6 million for PYRUKYND® (mitapivat) in Q2 2024, reflecting a 5% sequential increase from Q1 2024, with a total of 201 unique patients enrolled [3][5] Thalassemia Developments - The Phase 3 ENERGIZE-T study met primary and key secondary endpoints for mitapivat in adults with transfusion-dependent thalassemia [3] - Positive results from the Phase 3 ENERGIZE study were presented at the European Hematology Association 2024 Congress, demonstrating mitapivat's efficacy in non-transfusion-dependent thalassemia [3] Pediatric PK Deficiency - Topline data from the Phase 3 ACTIVATE-KidsT study of mitapivat in children with PK deficiency was announced, marking the first study to report safety and efficacy data in this demographic [3][4] - Enrollment for the Phase 3 ACTIVATE-Kids study in children not regularly transfused has been completed, with topline data expected in 2025 [3][4] Financial Performance - For Q2 2024, Agios reported a net loss of $96.1 million, compared to a net loss of $83.8 million in Q2 2023 [5][6] - Research and Development (R&D) expenses increased to $77.4 million in Q2 2024 from $68.9 million in Q2 2023, primarily due to costs associated with the siRNA TMPRSS6 program [5][6] - Cash, cash equivalents, and marketable securities totaled $645.3 million as of June 30, 2024, down from $806.4 million at the end of 2023 [6][12] Corporate Development - Agios entered a distribution agreement with NewBridge Pharmaceuticals to commercialize PYRUKYND® in the Gulf Cooperation Council (GCC) region [3] - The company anticipates filing an sNDA for mitapivat in thalassemia and completing enrollment in the Phase 3 RISE UP study for sickle cell disease by the end of 2024 [4]

– ACTIVATE-KidsT is Agios’ First Pediatric Data Readout;Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adultswith PK Deficiency Who are Regularly Transfused – – Prespecified Statistical Criterion for the Primary Endpoint in ACTIVATE-KidsT Was Not Met; Results Were Clinically Meaningful, with Observed Response Rates Higher for Mitapivat than Placebo for the Primary Endpoint of Transfusion Reduction Response and for the Secondary Endpoints of Transfusion-Free Response and N ...

The market expects Agios Pharmaceuticals (AGIO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 1, 2024, might help the stock move higher if these key numbe ...

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's w ...